This is a regulatory disclosure submitted to BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
A meeting of the Board of Directors of Bafna Pharmaceuticals Limited is scheduled to be held on Wednesday, November 11, 2026. The primary agenda for the meeting is to consider and approve the un-audited financial results of the company for the quarter and half-year ended September 30, 2026.
In accordance with the company's Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the company's shares by designated persons and their immediate relatives remains closed. The closure period is from October 1, 2026, to November 13, 2026 (both days inclusive). This closure is specifically for the purpose of considering the aforementioned un-audited financial results for Q2 and H1 FY27.
The document is digitally signed by Mohanachandran A, who holds the position of Company Secretary & Compliance Officer, on November 06, 2026, at 11:18:03 IST.